288
A. S. Shinde et al.
17. Mohanraj VJ, Chen Y (2006) Nanoparticles—a review
18. Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup
Med Toxicol 2:16–22. https://doi.org/10.1186/1745-6673-2-16
19. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res 46:6387–6392
20. Chowdhury A, Kunjiappan S, Panneerselvam T, Somasundaram B, Bhattacharjee C (2017)
Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases. Int
Nano Lett 7:91–122. https://doi.org/10.1007/s40089-017-0208-0
21. He C, Hu Y, Yin L, Tang C, Yin C (2010) Effects of particle size and surface charge on cellular
uptake and biodistribution of polymeric nanoparticles. Biomaterials 31:3657–3666. https://
doi.org/10.1016/j.biomaterials.2010.01.065
22. Barreto JA, O’Malley W, Kubeil M, Graham B, Stephan H, Spiccia L (2011) Nanomaterials:
applications in cancer imaging and therapy. Adv Mater 23:H18–H40. https://doi.org/10.1002/
adma.201100140
23. Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of
anti-angiogenic cancer therapy. Drug Resist Updat 13:16–28. https://doi.org/10.1016/j.drup.
2009.12.001
24. Guo X, Shi C, Yang G, Wang J, Cai Z, Zhou S (2014) Dual-responsive polymer micelles for
target-cell-specific anticancer drug delivery. Chem Mater 26:4405–4418. https://doi.org/10.
1021/cm5012718
25. Bae YH, Park K (2011) Targeted drug delivery to tumors: myths, reality and possibility. J
Control Release 153:198–205. https://doi.org/10.1016/j.jconrel.2011.06.001
26. Kumar A, Ma H, Zhang X, Huang K, Jin S, Liu J, Wei T, Cao W, Zou G, Liang XJ (2012)
Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment.
Biomaterials 33:1180–1189. https://doi.org/10.1016/j.biomaterials.2011.10.058
27. Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a
new form of chemotherapy. Cancer Invest 19:424–436
28. Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR (2004) Synthesis and in vitro
testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug
Chem 15:1174–1181. https://doi.org/10.1021/bc0499127
29. Low PS, Henne WA, Doorneweerd DD (2008) Discovery and development of folic-acid-based
receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem
Res 41:120–129. https://doi.org/10.1021/ar7000815
30. Cheng Z, Al Zaki A, Hui J, Muzykantov VR, Tsourkas A (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338:903–910
31. Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature
501:328–337
32. Davis ME (2009) The first targeted delivery of sirna in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659–668. https://doi.
org/10.1021/mp900015y
33. Slowing II, Vivero-Escoto JL, Wu CW, Lin VSY (2008) Mesoporous silica nanoparticles as
controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60:1278–
1288
34. Chen S, Zhang Q, Hou Y, Zhang J, Liang XJ (2013) Nanomaterials in medicine and pharmaceuticals: nanoscale materials developed with less toxicity and more efficacy. Eur J Nanomed
5:61–79. https://doi.org/10.1515/ejnm-2013-0003
35. Tang F, Li L, Chen D (2012) Mesoporous silica nanoparticles: synthesis, biocompatibility
and drug delivery. Adv Mater 24:1504–1534. https://doi.org/10.1002/adma.201104763
36. Hu X, Hao X, Wu Y, Zhang J, Zhang X, Wang PC, Zou G, Liang X (2013) Multifunctional
hybrid silica nanoparticles for controlled doxorubicin loading and release with thermal and
pH dual response. J Mater Chem B 1:1109–1118
37. Peer D, Margalit R (2006) Fluoxetine and reversal of multidrug resistance. Cancer Lett
237:180–187
A. S. Shinde et al.
17. Mohanraj VJ, Chen Y (2006) Nanoparticles—a review
18. Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup
Med Toxicol 2:16–22. https://doi.org/10.1186/1745-6673-2-16
19. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res 46:6387–6392
20. Chowdhury A, Kunjiappan S, Panneerselvam T, Somasundaram B, Bhattacharjee C (2017)
Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases. Int
Nano Lett 7:91–122. https://doi.org/10.1007/s40089-017-0208-0
21. He C, Hu Y, Yin L, Tang C, Yin C (2010) Effects of particle size and surface charge on cellular
uptake and biodistribution of polymeric nanoparticles. Biomaterials 31:3657–3666. https://
doi.org/10.1016/j.biomaterials.2010.01.065
22. Barreto JA, O’Malley W, Kubeil M, Graham B, Stephan H, Spiccia L (2011) Nanomaterials:
applications in cancer imaging and therapy. Adv Mater 23:H18–H40. https://doi.org/10.1002/
adma.201100140
23. Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of
anti-angiogenic cancer therapy. Drug Resist Updat 13:16–28. https://doi.org/10.1016/j.drup.
2009.12.001
24. Guo X, Shi C, Yang G, Wang J, Cai Z, Zhou S (2014) Dual-responsive polymer micelles for
target-cell-specific anticancer drug delivery. Chem Mater 26:4405–4418. https://doi.org/10.
1021/cm5012718
25. Bae YH, Park K (2011) Targeted drug delivery to tumors: myths, reality and possibility. J
Control Release 153:198–205. https://doi.org/10.1016/j.jconrel.2011.06.001
26. Kumar A, Ma H, Zhang X, Huang K, Jin S, Liu J, Wei T, Cao W, Zou G, Liang XJ (2012)
Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment.
Biomaterials 33:1180–1189. https://doi.org/10.1016/j.biomaterials.2011.10.058
27. Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a
new form of chemotherapy. Cancer Invest 19:424–436
28. Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR (2004) Synthesis and in vitro
testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug
Chem 15:1174–1181. https://doi.org/10.1021/bc0499127
29. Low PS, Henne WA, Doorneweerd DD (2008) Discovery and development of folic-acid-based
receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem
Res 41:120–129. https://doi.org/10.1021/ar7000815
30. Cheng Z, Al Zaki A, Hui J, Muzykantov VR, Tsourkas A (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338:903–910
31. Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature
501:328–337
32. Davis ME (2009) The first targeted delivery of sirna in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659–668. https://doi.
org/10.1021/mp900015y
33. Slowing II, Vivero-Escoto JL, Wu CW, Lin VSY (2008) Mesoporous silica nanoparticles as
controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60:1278–
1288
34. Chen S, Zhang Q, Hou Y, Zhang J, Liang XJ (2013) Nanomaterials in medicine and pharmaceuticals: nanoscale materials developed with less toxicity and more efficacy. Eur J Nanomed
5:61–79. https://doi.org/10.1515/ejnm-2013-0003
35. Tang F, Li L, Chen D (2012) Mesoporous silica nanoparticles: synthesis, biocompatibility
and drug delivery. Adv Mater 24:1504–1534. https://doi.org/10.1002/adma.201104763
36. Hu X, Hao X, Wu Y, Zhang J, Zhang X, Wang PC, Zou G, Liang X (2013) Multifunctional
hybrid silica nanoparticles for controlled doxorubicin loading and release with thermal and
pH dual response. J Mater Chem B 1:1109–1118
37. Peer D, Margalit R (2006) Fluoxetine and reversal of multidrug resistance. Cancer Lett
237:180–187